P3H2

Across TCGA pan-cancer cohorts, P3H2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated P3H2 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher P3H2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated P3H2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where P3H2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.598	0.869	<.001	109	view →
LUAD	OS	Median	All	0.917	1.000	<.001	28	view →
GBM	DFS	Median	All	0.262	0.509	.006	9	view →
UCEC	DFS	Quartile	All	0.777	1.000	.008	8	view →
LSCC	DFS	Median	All	0.888	0.991	.006	4	view →
PDAC	DFS	Median	III,IV	0.479	0.253	.040	2	view →
HNSC	OS	Median	III,IV	0.562	0.777	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

P3H2–CCRCC (DFS)

Open the CCRCC breakdown →